Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY900003 plus Gemcitabine and Carboplatin in Advanced NSCLC
NCT00042679Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2002
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 1
01
Overview
A Phase 2 trial of aprinocarsen in non-small cell lung cancer (NSCLC), sponsored by Eli Lilly and Company. Started Jun 2002; status: completed.
02
Drugs
aprinocarsen
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00042679.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00042679.